PMID- 32790920
OWN - NLM
STAT- MEDLINE
DCOM- 20210323
LR  - 20210323
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Linking)
VI  - 191
IP  - 5
DP  - 2020 Dec
TI  - Direct-acting antiviral agents for hepatitis C virus-mixed cryoglobulinaemia: 
      dissociated virological and haematological responses.
PG  - 775-783
LID - 10.1111/bjh.17036 [doi]
AB  - The hepatitis C virus-positive (HCV+) mixed cryoglobulinaemia (MC) is associated 
      with haematological alterations such as monoclonal B-cell lymphocytosis or 
      non-Hodgkin lymphomas (NHLs). Antiviral therapy for MC, based on interferon and 
      ribavirin, has been shown to be able to eliminate the viral replication as well 
      as the B-cell monoclonal alterations. Many studies have reported the efficacy of 
      direct-acting antivirals (DAAs) in the treatment of HCV+ MC. However, some 
      authors noticed the persistence of haematological diseases despite HCV 
      eradication. To verify the effects of DAAs on B-cell proliferation, we evaluated 
      67 patients with HCV+ MC. Six patients had an overt NHL and 30% had monoclonal 
      B-lymphocytosis. In 20% of the patients, the mutation L265P of the myeloid 
      differentiation factor 88 (MYD88) gene was detected in peripheral blood. All 
      patients had negative HCV viraemia at week 12; one had a breakthrough, while two 
      cases relapsed. A complete clinical response of vasculitis was seen in 60% of the 
      patients. Among the six patients with NHL, one showed a complete response, 
      whereas in the others there were no changes in the number and size of the nodes. 
      Among the patients carrying a clonal population in peripheral blood, only 22% 
      became negative. These data indicate that DAAs are not able to eliminate the 
      clonal alterations induced by HCV in a large proportion of cases.
CI  - (c) 2020 British Society for Haematology and John Wiley & Sons Ltd.
FAU - Pozzato, Gabriele
AU  - Pozzato G
AUID- ORCID: 0000-0002-7805-8398
AD  - Department of Clinical and Surgical Sciences, University of Trieste, Trieste, 
      Italy.
FAU - Mazzaro, Cesare
AU  - Mazzaro C
AD  - Clinical and Experimental Onco-Haematology Unit, CRO Aviano National Cancer 
      Institute IRCCS, Aviano, Italy.
FAU - Artemova, Marina
AU  - Artemova M
AD  - Department of Fundamental Medicine, Moscow State University, Moscow, Russia.
FAU - Abdurakhmanov, Dzhamal
AU  - Abdurakhmanov D
AD  - I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
FAU - Grassi, Gabriele
AU  - Grassi G
AD  - Department of Life Sciences, University of Trieste, Trieste, Italy.
FAU - Crosato, Ivo
AU  - Crosato I
AD  - Department of Clinical and Surgical Sciences, University of Trieste, Trieste, 
      Italy.
FAU - Mauro, Endri
AU  - Mauro E
AD  - Department of Internal Medicine, Pordenone General Hospital, Pordenone, Italy.
FAU - Ghersetti, Michela
AU  - Ghersetti M
AD  - Department of Internal Medicine, Pordenone General Hospital, Pordenone, Italy.
FAU - Zorat, Francesca
AU  - Zorat F
AD  - Department of Clinical and Surgical Sciences, University of Trieste, Trieste, 
      Italy.
FAU - Bomben, Riccardo
AU  - Bomben R
AD  - Clinical and Experimental Onco-Haematology Unit, CRO Aviano National Cancer 
      Institute IRCCS, Aviano, Italy.
FAU - Bulian, Pietro
AU  - Bulian P
AD  - Clinical and Experimental Onco-Haematology Unit, CRO Aviano National Cancer 
      Institute IRCCS, Aviano, Italy.
FAU - Gattei, Valter
AU  - Gattei V
AD  - Clinical and Experimental Onco-Haematology Unit, CRO Aviano National Cancer 
      Institute IRCCS, Aviano, Italy.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200813
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Antiviral Agents)
RN  - 0 (MYD88 protein, human)
RN  - 0 (Myeloid Differentiation Factor 88)
SB  - IM
CIN - Br J Haematol. 2020 Dec;191(5):661-662. PMID: 32808671
MH  - Adult
MH  - Aged
MH  - Amino Acid Substitution
MH  - *Antiviral Agents/administration & dosage/adverse effects
MH  - *Cryoglobulinemia/blood/chemically induced/genetics
MH  - Female
MH  - Hepacivirus/genetics/*metabolism
MH  - *Hepatitis C/blood/drug therapy/genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Mutation, Missense
MH  - *Myeloid Differentiation Factor 88/blood/genetics
MH  - Viremia/blood/genetics
OTO - NOTNLM
OT  - direct antiviral agents
OT  - hepatitis C virus
OT  - interferon
OT  - mixed cryoglobulinaemia
OT  - non-Hodgkin lymphoma
OT  - ribavirin
EDAT- 2020/08/14 06:00
MHDA- 2021/03/24 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/06/18 00:00 [received]
PHST- 2020/06/30 00:00 [accepted]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/03/24 06:00 [medline]
PHST- 2020/08/14 06:00 [entrez]
AID - 10.1111/bjh.17036 [doi]
PST - ppublish
SO  - Br J Haematol. 2020 Dec;191(5):775-783. doi: 10.1111/bjh.17036. Epub 2020 Aug 13.